Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’ s Halaven. Issues draft guidance recommending against second-line use in breast cancer. ... Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to

Latest news

NICE backs Eisai's Halaven for breast cancer

NICE backs Eisai's Halaven for breast cancer. Reverses 2012 rejection due to new data and patient access discount. ... NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug.
Lilly closes on first approval for sarcoma drug Lartruvo

If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Eisai gets green light for Lenvima in kidney cancer

Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Oncology directions

Halaven (eribulin).
Disappointment for pharma with new Cancer Drugs Fund list

While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “ ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who
Country report: The healthcare market in Japan

The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager: Negotiable

Associate Scientific Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Senior Medical Writer: Salary is DOE

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Graduate Scientific Editor: DOE

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Healthcare PR Senior Account Manager: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Market Access Consultant - Greater Manchester: Negotiable

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....